

## United States Patent and Trademark Office



APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/940,166	08/27/2001	Gregory S. Blank	PI105RIDICI	5378
9157	7590 03/11/2003			
GENENTECH, INC.			EXAMINER	
1 DNA WAY SOUTH SAN FRANCISCO, CA 94080			SAUNDERS, DAVID A	
			ART UNIT	PAPER NUMBER
			1644	7
			DATE MAILED: 03/11/2003	

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No. Applicant(s)  O 4/4 441 // BIAND etal
Office Action Summary	Application No. Applicant(s)  0 4/6 40 /66 BLAND ETA  Examiner  5 AUND ERS Group Art Unit 1644
The MAILING DATE of this communication appears	on the cover sheet beneath the correspondence address-
Period for Reply	3
OF THIS COMMUNICATION.	EXPIRE MONTH(S) FROM THE MAILING DATE
	36(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS by within the statutory minimum of thirty (30) days will be considered timely. Expire SIX (6) MONTHS from the mailing date of this communication.  The content of the communication of
Status	
Defesponsive to communication(s) filed on 8/27/0	?/
This action is FINAL.	
<ul> <li>Since this application is in condition for allowance except the accordance with the practice under Ex parte Quayle, 1935</li> </ul>	or formal matters, <b>prosecution as to the merits is closed</b> in C.D. 1 1; 453 O.G. 213.
Disposition of Claims	is love ponding in the application
Claim(s)	is/are pending in the application.
Of the above claim(s)	is/are withdrawn from consideration.
☐ Claim(s)	Is/are allowed.
4 Claim(s) 2 0	is/are rejected.
□ Claim(s)	
□ Claim(s)————	are subject to restriction or election requirement.
Application Papers	
☐ See the attached Notice of Draftsperson's Patent Drawing	Review, PTO-948.
☐ The proposed drawing correction, filed on	is approved disapproved.
☐ The drawing(s) filed on is/are object	ed to by the Examinor.
<ul> <li>☐ The specification is objected to by the Examiner.</li> <li>☐ The oath or declaration is objected to by the Examiner.</li> </ul>	
Priority under 35 U.S.C. § 119 (a)-(d)	
<ul> <li>□ Acknowledgment is made of a claim for foreign priority us</li> <li>□ All □ Some* □ None of the CERTIFIED copies of</li> <li>□ received.</li> <li>□ received in Application No. (Series Code/Serial Numb</li> </ul>	er)
received in this national stage application from the Interview copies not received:	
Attachment(s)	No(s) Interview Summary, PTO-413
☐ Information Disclosure Statement(s), PTO-1449, Paper N	□ Notice of Informal Patent Application, PTO-15
Notice of Reference(s) Cited, PTO-892	
☐ Notice of Draftsperson's Patent Drawing Review, PTO-94	
Offic	e Action Summary

U. S. Patent and Trademark Office PTO-326 (Rev. 9-97)

Part of Paper No.

Application/Control Number: 09/940,166 Page 2

Art Unit: 1644

The amendment of 8/27/01 has been entered. Claim 20 is pending and under examination.

The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. See *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970);and, *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321© may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent is shown to be commonly owned with this application. See 37 CFR 1.130(b).

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

Claim 20 is rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claim 1 of U.S. Patent No. 6,322,997. Although the conflicting claims are not identical, they are not patentably distinct from each other because

Page 3 Application/Control Number: 09/940,166

Art Unit: 1644

instant claim 20 is recited precisely the same as issued claim 1, except for the fact that claim 20 contains a "wherein" clause that limits the antigen-binding specificity of the antibody.

Instant claim 20 thus falls within the scope of what is encompassed by issued claim. A disclaimer is required in order to assure that the '977 patent and any patent issued instantly remain under common ownership.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to David A. Saunders, Ph.D., whose telephone number is (703) 308-3976. The examiner can normally be reached on Monday-Thursday from 8:00 a.m. to 5:30 p.m. The examiner can also be reached on alternate Fridays.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Christina Chan, can be reached on (703) 308-3973. The fax phone number for the organization where this application or proceeding is assigned is (703) 308-4242.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-0196.

D. Saunders:jmr

February 25, 2003

DAVID SAUNDERS
PRIMARY EXAMINER
ART UNIT 182 /644